Search is Powered by Google
Pharma Industry / Biotech Industry News

Pharmaceutical Industry Shifts Focus Of Lobbying Efforts To State Level

Main Category: Pharma Industry / Biotech Industry
Article Date: 30 Aug 2007 - 14:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Lobbyists for the pharmaceutical industry increasingly are targeting state lawmakers as "drug makers find themselves on the defensive, facing tighter regulations and restrictions in many states," the Newark Star-Ledger reports. Lawmakers in various states -- who "maintain they are acting to fill a vacuum left by Congress" -- have debated legislation that would reduce prescription drug prices; require drug makers to disclose spending on marketing, including gifts and payments to physicians; and restrict the commercial use of physician prescription data, according to the Star-Ledger.

Other legislation introduced by state lawmakers would regulate drug industry sales representatives, require publication of all clinical trial data about drug safety and efficacy, and restrict advertising on electronic prescribing software used by physicians and pharmacists. West Virginia Delegate Don Perdue (D), chair of the state House of Delegates Health and Human Resources Committee, said, "Change has to happen in the states because nothing meaningful is happening at the federal level, where the drug lobby is too strong."

However, Jan Faiks, vice president of government affairs and law for the Pharmaceutical Research and Manufacturers of America, said that many state bills meant to regulate the drug industry are "unnecessary" and based on "misleading arguments." Faiks said that sponsors of the bills often are critics of the health care system in general and do not recognize that prescription drug spending accounts for just 10% of total health care costs (Cohen, Newark Star-Ledger, 8/26).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
U.S. FDA Approves Requip® XL™, The First And Only Oral Once-daily Non-ergot Dopamine Agonist For Parkinson's Disease
15 Jun 2008
GlaxoSmithKline announced the approval of Requip® XL™(ropinirole extended-release tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease...


Involving Your Kids in Their Nutrition
Involving Your Kids in Their Nutrition

Nutrition experts recommend getting your kids involved in their nutrition decisions, and making sure they understand why good nutrition is important.

more videos are available in our health videos section.